Table 2.

Key papers and their related key findings

Paper	Findings
[1] Pushpakom S et al. Nat Rev Drug Discov 2019; 18(1): 41–58. https://doi.org/10.1038/nrd.2018.168	Recommended innovative ways to overcome challenges in repurposing approach
[5] March‐Vila E et al. Front Pharmacol 2017; 8: 298–298. https://doi.org/10.3389/fphar.2017.00298	Computational approaches for repurposing
[6] Iwata H et al. J Chem Inf Model 2015; 55(2): 446–459. https://doi.org/10.1021/ci500670q	Drug repurposing for neurodegenerative diseases: the in silico tools
[7] Dovrolis N et al. Drug Discov Today 2017; 22(5): 805–813. https://doi.org/10.1016/j.drudis.2017.03.009	In silico tools to establish drug‐disease association network and newly predicted drug indications
[20] Zhang M et al. PLoS One 2016; 11(12). https://doi.org/10.1371/journal.pone.0168812	Omics data mining for repurposing
[22] Brown AS, Patel CJ. Sci Data 2017; 4. https://doi.org/10.1038/sdata.2017.29	Computational repurposing based on a database of approved and failed drugs and their indications